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Abstract
Objective. To evaluate expression of potential molecular ima-
ging targets epidermal growth factor receptor (EGFR), gly-
coprotein nonmetastatic melanoma protein B (GPNMB),
and vascular endothelial growth factor (VEGF) in lymph
nodes (LNs) with or without head and neck squamous cell
carcinoma (HNSCC) metastases after (chemo)radiation.
Study Design. Retrospective study comparing receptor
expression in paired lymph nodes after initial treatment.
Setting. A tertiary referral hospital.
Subjects and Methods. Salvage neck dissection specimens of
40 patients treated with (chemo)radiation were selected.
LNs that contained viable tumor, reactive changes after ini-
tial treatment, and normal LNs were analyzed using immu-
nohistochemically determined H-scores and by calculating
sensitivity and specificity rates and positive/negative predic-
tive values (PPVs/NPVs).
Results. EGFR expression was found in 86% and GPNMB
expression in 100% of the LNs with viable tumor. VEGF
expression was present in all lymph node types. For EGFR,
the sensitivity rate was 86%, and specificity rate was 81%.
For GPNMB, these were 100% and 75%, respectively. PPV of
EGFR was 61.8% and NPV was 98.2%. These were 56.4%
and 100% for GPNMB, respectively.
Conclusion. In residual or recurrent HNSCC lymph node
metastases, both EGFR and GPNMB show tumor-specific
expression in immunohistochemistry, which may prove
useful in future molecular imaging in salvage neck dissec-
tions. Immunohistochemically detected VEGF expression
indicates that this target is not feasible for imaging purposes
in salvage surgery. Therefore, GPNMB could be a new
potential imaging target showing comparable results to
EGFR in immunohistochemistry.
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H
ead and neck squamous cell carcinoma (HNSCC)
presents with cervical lymph node metastasis in
60% of patients at the time of diagnosis.1 After pri-
mary treatment, .50% of the patients with locally advanced
HNSCC develop recurrence within 2 years.1 When residual
or recurrent metastatic disease after previous (chemo)radia-
tion is resectable, salvage surgery may be performed to cure
the patient.1
Despite these therapeutic attempts, treatment of HNSCC
remains a challenge with a median survival of 6 to 9 months
in patients with recurrent or metastatic HNSCC who have
run out of therapeutic options.2
After preoperative imaging with computed tomography
(CT), positron emission tomography (PET)–CT, or magnetic
resonance imaging (MRI), intraoperative surgical decisions
are mainly based on visual inspection and palpation. The
effects of radiotherapy (eg, necrosis, fibrosis) complicate the
surgical procedure. In initially treated patients, conventional
imaging techniques are unsatisfactory for reliable detection
and delineation of regional recurrences, since viable tumor is
found in only 41% of salvage neck dissections.3 Positive
margins are found in up to 31% of salvage neck dissections
compared to 9% of primary neck dissections and are associ-
ated with diminished regional control rates.4-6
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Better visualization and detection of involved lymph
nodes might reduce both positive margins, as the extent of
surgery. This is especially important in salvage neck dissec-
tions, which are associated with high complication rates.7
Intraoperative imaging using near-infrared (NIR) light is a
new imaging modality that could be helpful in the surgical
judgment during resections.8
The fluorophore IRDye800, which can be conjugated
with an antibody, is with excitation/emission wavelengths of
774/789 nm within the optimal range for (NIR) fluorescence
imaging and has shown promising results in HNSCC.9,10
The IRDye800 may be conjugated with cetuximab, an anti-
body that binds to the epidermal growth factor receptor
(EGFR) and is commonly overexpressed in HNSCC. In pre-
viously untreated cervical HNSCC lymph node metastases,
Rosenthal et al11 showed the possibility of NIR visualization
with high sensitivity and specificity using cetuximab-
IRDye800 during primary surgical treatment.
However, in patients with residual or recurrent lymph
node metastases, reactive changes (fibrosis, necrosis, and
calcifications) due to previous (chemo)radiation occur in
both lymph nodes and surrounding tissues. No research has
been conducted on how (chemo)radiation may affect recep-
tor expression in these lymph nodes. Immunohistochemical
receptor detection is the first step to identify new potential
imaging targets. EGFR, glycoprotein nonmetastatic mela-
noma protein B (GPNMB), and vascular endothelial growth
factor (VEGF) receptors are potential imaging targets, as
previous studies indicated them to be (over)expressed in
HNSCC.12-15 This study aims to evaluate receptor expression
of these potential NIR fluorescence imaging targets in sal-
vage neck dissections.
Methods
Fifty-five patients with mucosal HNSCC who had a salvage
neck dissection for radiological suspicion of residual or
recurrent disease after initial treatment with radiotherapy
with or without concomitant systemic treatment between
January 2005 and March 2015 at the University Medical
Center Groningen were included. Retrospectively, demo-
graphics of all patients, relevant medical and treatment history,
and human papillomavirus (HPV) status (for oropharyngeal
carcinoma) were collected (Table 1).
Reactive lymph nodes were defined as lymph nodes with
necrosis, fibrosis, or calcifications without viable tumor cells
present on hematoxylin and eosin (H&E)–stained micro-
scopic slide.
To avoid bias of preexisting variability in receptor expres-
sion between patients and tumors, we compared lymph
nodes per patient for expression. Therefore, only patients
with adjacent lymph nodes of at least 2 subtypes of lymph
nodes (with viable tumor, reactive changes due to initial
treatment or normal) were included. This led to exclusion of
15 patients because of unavailability of multiple lymph node
types, resulting in a study group of 40 patients, which was
used for further analyses (Figure 1). Lymph nodes were
preferably selected from the same neck level, but this was
not possible in all patients. Formalin-fixed and paraffin-
embedded blocks of the lymph nodes were gathered from
the archives of the Department of Pathology, and 3-mm sec-
tions were cut and stained for standard H&E, EGFR (3C6,
prediluted by supplier; Ventana Roche), GPNMB (clone
AF2550, dilution 1:200; R&D Systems), and VEGF-A (clone
A-20, dilution 1:50; Santa Cruz). Immunohistochemical stain-
ing of EGFR was performed on a BenchMark Ultra automated
stainer (Ventana Roche), according to the manufacturer’s pro-
tocol. For GPNMB and VEGF-A, the following immunostain-
ing protocol was performed: sections were deparaffinized and
rehydrated in a series of decreasing concentrations of alcohol.
Sections were then washed with demineralized water. For
GPNMB, antigen retrieval was performed by microwaving
the sections 15 minutes in 10 mM citrate buffer (pH 6.0).
Endogenous peroxidase reaction was blocked by incubating
the sections in 0.3% H2O2 in 50 mL phosphate-buffered
Table 1. Patient and Tumor Characteristics.
Characteristic Total No. (%)
Sex
Male 26 (65)
Female 14 (35)
Age, y
Mean 59
Range 44-75
HPV status
Positive 13 (33)
Negative 27 (67)
Treatment
Radiotherapy 13 (33)
Chemoradiotherapy 27 (67)
Lymph nodes
Viable tumor metastasis 22 (24)
Reactive changes after treatment 27 (30)
Normal 42 (46)
Primary tumor site
Oral cavity 1 (5)
Oropharynx 7 (32)
Hypopharynx 5 (23)
Larynx 9 (41)
T-classification
1 3 (14)
2 4 (18)
3 4 (18)
4 11 (50)
N-classification
0 3 (14)
1 1 (5)
2a 4 (18)
2b 3 (14)
2c 9 (41)
3 2 (9)
Abbreviation: HPV, human papillomavirus.
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saline (PBS) (0.15 M NaCl, 8.0 mM Na2HPO4 2 H2O, 1.5
mM KH2PO4, pH 7.4) for 30 minutes. The primary antibody
was diluted in PBS containing 1% bovine serum albumin
(BSA) and incubated for 1 hour. The secondary antibody
(polyclonal rabbit anti-goat [RAGPO], 1:100 diluted in PBS
containing 1% BSA and 1% AB-serum; DAKO) was incu-
bated for 30 minutes, after which the tertiary antibody (poly-
clonal goat anti-rabbit [GARPO], 1:100 diluted in PBS
containing 1% BSA and 1% AB-serum; DAKO) was incu-
bated for 30 minutes. For VEGF-A, avidin/biotin was blocked
using a Blocking Kit (Vector Laboratories SP-2001). Primary
antibody was diluted in PBS containing 1% BSA and incubated
for 1 hour at room temperature. The secondary antibody (goat
anti-rabbit biotin [GARbio], 1:300 diluted in PBS containing
1% BSA and 1% AB-serum; DAKO) was incubated for 30
minutes, after which the tertiary antibody (streptavidin polyclo-
nal, 1:300 diluted in PBS containing 1% BSA and 1% AB-
serum; DAKO) was incubated for 30 minutes. Visualization for
both GPNMB and VEGF-A was performed using the diamino-
benzidine peroxidase reaction. Sections were counterstained
with hematoxylin and dehydrated in a series of increasing con-
centrations of alcohol.
After sectioning of the study slides, no viable tumor was
present in both the study H&E and additional stainings of 2
lymph nodes that were tumor positive on the diagnostic
H&E. These lymph nodes were excluded from further
analysis. From these patients, a normal and a reactive lymph
node were still available for analysis. Statistical analysis was
therefore performed on 91 lymph nodes (of 40 patients) of
which 22 contained viable tumor, 27 showed reactive
changes, and 42 were normal (Table 1). The division of
matched lymph nodes for all patients is shown in Table 2.
Three patients who received a bilateral neck dissection have
lymph nodes included from both sides.
Antibody staining was evaluated independently by 2 of
the investigators (JvS and BvdV, who is a dedicated head
and neck pathologist). Lymph node staining was scored on
both percentage of positive tumor cells and intensity of the
staining. Intensity of staining was scored as strong (21),
weak (11), and negative (0). H-scores were calculated by
multiplying the intensity of the staining with the percentage
of positive tumor cells. The H-score ranges from 0 (no
staining) to 200 (all tumor cells strongly positive).
Lymph nodes with viable tumor were classified as either
positive (H-score 5) or negative (H-score \5).
Receptor expression was also evaluated in lymph nodes
with viable tumor and lymph nodes with reactive changes in
relation to the initial treatment (ie, radiotherapy or chemora-
diation) and in normal lymph nodes.
Based on the Dutch Medical Research Law (Wet medisch-
wetenschappelijk onderzoek met mensen [WMO]), no assess-
ment was required by the hospital’s institutional review board.
Figure 1. Inclusion process of patients and their lymph nodes.
Table 2. Distribution of Matched Lymph Nodes per Type (Normal, With Reactive Changes, With Viable Tumor) From All Patients, Stratified
for Initial Treatment.
Characteristic Normal 1 Reactive, No. Normal 1 Viable, No. Normal 1 Reactive 1 Viable, No.
Radiotherapy 2 8 3
Chemoradiation 19 5 3
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Statistical Analysis
Groups were compared using the Mann-Whitney U test for
nonparametric data, considering P \ .05 to be statistically
significant. Sensitivity, specificity, accuracy, positive pre-
dicting value (PPV), and negative predicting value (NPV)
were calculated. Statistical analyses were performed using
SPSS (version 23 for Windows; SPSS, Inc).
Results
Patients
Of the 40 patients available for analysis, 26 were male
(65%) and 14 were female (35%) (Table 1). The median
age was 59 (range, 44-75) years. The mean follow-up time
for patients with viable tumor was 27.6 (3.8-100.5) months.
Thirteen patients had an HPV-positive primary tumor.
Thirteen patients were treated with radiotherapy and 27
received chemoradiation.
Receptor Expression
In lymph nodes with viable tumor, EGFR was expressed in
.25% of viable tumor cells in 68% of lymph nodes with viable
tumor, compared to 100% for GPNMB (Table 3). Necrosis
(partly) showed nonspecific staining in 95% and 100% of lymph
nodes with viable tumor for EGFR and GPNMB, respectively.
In lymph nodes with reactive changes, GPNMB also
showed higher nonspecific staining in necrosis. Fibrosis and
cholesterol clefts only showed staining in 1 (EGFR) or 2
(GPNMB) lymph nodes, and calcifications did not stain in
any of the lymph nodes.
Receptor expression of EGFR and GPNMB was absent in
normal lymph nodes, except for a few histiocytes that
showed GPNMB staining. VEGF showed weak to strong
receptor expression in all lymph nodes with specific staining
of both normal lymphoid cells as well as of viable tumor
cells or necrosis (Figure 2).
Disregarding the staining of fibrosis and cholesterol clefts
in 1 or 2 slides, nonspecific staining was only seen in regions
of necrosis. Therefore, any further mentions of nonspecific
staining will indicate necrosis.
The highest median H-score was seen in regional lymph
node metastases from laryngeal carcinomas stained for
EGFR, with a median (SD) of 160 (63.2; range, 10-200). For
GPNMB, the medians of the different HNSCC sites lie at
around 100. The median H-score was 95 for EGFR and 100
for GPNMB. The distribution of H-scores can be seen in
Figure 3A.
Receptor Expression in Relation to Initial Treatment
Out of 22 lymph nodes with viable tumor, 12 were treated
with radiotherapy. All (100%) lymph nodes with viable
tumor showed an H-score of 5 for EGFR and GPNMB.
For the lymph nodes treated with chemoradiation, this was 7
(70%) for EGFR and 10 (100%) for GPNMB.
The H-score of EGFR was slightly but not significantly
higher in lymph nodes after radiotherapy compared to che-
moradiation (P = .137) (Figure 3B).
No differences were found within 1 HNSCC site and
among sites between radiotherapy and chemoradiation for
both EGFR and GPNMB.
Table 3. EGFR, GPNMB, and VEGF Receptor Expression in the Different Types of Lymph Nodes and in Relation to Initial Treatment.
Receptor expression EGFR, % GPNMB, % VEGF, % No.
Viable tumor 22
5% of viable tumor cells stained 86 100 100 22
25% of viable tumor cells stained 68 100 100 22
Necrosis stained (% of nodes) 95 100 100 22
Positive predictive valuea 62 56 24
Negative predictive valuea 98 100
Reactive changes 27
Viable cells 0 0 100 27
Necrosis stained (% of nodes) 72 94 100 18
Normal lymph nodes 0 0 100 42
In relation to treatment 22
Viable tumor 5% of viable tumor cells stained
Radiotherapy 100 100 100 12
Chemoradiotherapy 70 100 100 10
Reactive changes necrosis stained (% of nodes)
Radiotherapy 75 100 100 4
Chemoradiotherapy 71 93 100 14
Abbreviations: EGFR, epidermal growth factor receptor; GPNMB, glycoprotein nonmetastatic melanoma protein B; VEGF, vascular endothelial growth factor.
aPositive predictive values and negative predictive values were calculated taking necrosis into account.
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Sensitivity, Specificity, and Positive and Negative
Predictive Values
When any presence of staining (ie, both viable tumor cells as
well as necrotic areas) was considered as ‘‘positive’’ and
complete absence as ‘‘negative,’’ EGFR sensitivity was 86%
and specificity was 81%. For GPNMB, sensitivity was 100%
and specificity was 75%. The PPV and NPV of EGFR were
61.8% and 98.2%, respectively. For GPNMB, the PPV was
56.4%, and NPV was 100.0% (Table 3).
When only viable cells were evaluated (ie, stained necro-
tic areas were ignored), sensitivity rates remained 86% for
EGFR and 100% for GPNMB. The specificity rate was
100% for both EGFR and GPNMB, as none of the viable
lymph nodes showed expression other than in viable tumor
cells.
Discussion
To our knowledge, this is the first study to evaluate EGFR,
GPNMB, and VEGF expression in lymph node metastases
and adjacent lymph nodes without viable tumor in salvage
neck dissection specimens. Using immunohistochemical
detection, we revealed GPNMB as a potential imaging target
after previous (chemo)radiation.
Although lymph node numbers of this study are relatively
low, the results are based on a matched analysis of lymph
node subtypes within the same patient as comparing lymph
node subtypes from different patients might introduce bias
Figure 2. HE, EGFR, GPNMB, and VEGF staining of the 3 types of lymph nodes. EGFR, epidermal growth factor receptor; GPNMB, glyco-
protein nonmetastatic melanoma protein B; HE, hematoxylin and eosin; VEGF, vascular endothelial growth factor.
Figure 3. Distribution of H-scores in viable tumor metastases for EGFR and GPNMB (A), and in relation to initial treatment (B). EGFR, epi-
dermal growth factor receptor; GPNMB, glycoprotein nonmetastatic melanoma protein B.
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due to interindividual differences. To minimize the influence
of interindividual differences, we have decided to only
include patients in whom we could match 2 or 3 types of
lymph nodes (Table 2) at the cost of including a greater
number of patients in our analysis.
VEGF receptor expression was seen in all lymph nodes,
regardless of its type. This could possibly be because
patients in this cohort had recurrent or residual disease after
either radiotherapy or chemoradiation and may therefore
have had radioresistant tumors. Hypoxic tumors are known
to be relatively radiotherapy resistant and have been shown
to elevate systemic VEGF levels.16,17 However, we have not
used hypoxia markers in the present study. Both internal and
external positive and negative controls showed specific
staining for VEGF, ruling out nonspecific staining as a cause
for the extensive staining of VEGF.
In the evaluation of potential targets for molecular ima-
ging in the detection of cervical lymph node metastasis in
salvage surgery, a few factors should be considered. First of
all, it should be sensitive for viable tumor cells (ie, ideally,
all viable tumors should be stained). In this study, we
assumed that all cells deemed viable tumor cells in immuno-
histochemical analysis have indeed been viable tumor cells
in vivo. Second, it should be tumor specific, meaning that
surrounding tissues and lymph nodes without viable tumor
(either normal or with reactive changes) should not show
staining. This would lead to the highest tumor-to-background
ratios (TBRs; ie, tumor lighting up more brightly than sur-
rounding tissues) and therefore assist in the intraoperative
detection of HNSCC metastases.
In the case of salvage neck dissection patients, it is espe-
cially important that all lymph nodes containing viable
tumor cells are detected. Leaving any positive lymph node
behind has dramatic consequences for the prognosis of these
patients, without any other treatment options remaining.
Therefore, the surgeon must be absolutely sure that all non-
resected lymph nodes do not contain any tumor (high NPV).
Whether all positively stained lymph nodes do contain
viable tumor cells (PPV) is less relevant for survival, as long
as all viable tumor is detected and removed. However, unne-
cessary extended surgery may lead to loss of function and
declined quality of life.
Necrosis was present in two-thirds of lymph nodes with
reactive changes and showed EGFR and GPNMB staining in
the majority of lymph nodes. As there were no viable tumor
cells present in these lymph nodes, this staining would lead
to false positives when trying to detect viable tumor metas-
tases. However, this necrosis could possibly point to areas
with tumor remnants since it resembled degraded tumor cells
and was found in the same area as the lymph nodes contain-
ing viable metastatic tumor tissue.
No EGFR or GPNMB expression was found in normal
lymph nodes, accentuating the high NPV of the markers.
This could assist in the identification of lymph node levels
that are not suspected to contain viable tumor metastases.
By immunohistochemical evaluation of viable cells, only
tumor cells stained; all other cells were negative, leading to
a 100% PPV and 96% NPV with EGFR staining and 100%
PPV and 100% NPV with GPNMB staining. Macroscopically,
however, as seen in intraoperative imaging, necrosis would
confound these findings. Including necrosis, we found a PPV
of 61.8% for EGFR, which is in line with the study by
Rosenthal et al,11 who reported a PPV of 51% for patients pri-
marily treated with a neck dissection using molecular imaging
in vivo.
As explained earlier, the NPVs are more relevant for
imaging purposes in salvage neck dissections. The NPVs
are very high, with 98.2% for EGFR and 100% for GPNMB,
meaning that every GPNMB-negative node indeed does not
contain any viable tumor cells. Therefore, the extent of
neck dissection and thereby also morbidity could be
reduced by leaving negative nodes behind. For instance, in
this study, if the resection of lymph nodes in this study was
based on GPNMB positivity, 52 of 69 tumor negative
lymph nodes would not have been removed unnecessarily.
Based on these immunohistochemically detected findings,
GPNMB would be a more suitable target for molecular
imaging than EGFR.
Another notable finding of our study is high EGFR
expression in lymph node metastases of laryngeal carcino-
mas. Treatment type could be of influence, as laryngeal car-
cinomas are mostly treated with radiotherapy, while other
HNSCCs were sites treated with chemoradiation in our
study. However, no significant difference was found in
EGFR expression in lymph nodes of patients treated with
radiotherapy and those treated with chemoradiation. This
finding may have importance in the future in the diagnostics
of neck metastases of unknown primary tumors; however, it
has to be further investigated.
A high TBR is essential in the identification of viable
tumor cells in NIR fluorescence imaging. Laryngeal carci-
noma seems to be the most suitable type of tumor, as it has
the highest median H-score of 160. It will therefore defi-
nitely light up more brightly than surrounding tissues and
necrosis expressing EGFR.
Another influence on EGFR expression is HPV-associated
p16 expression. HPV-positive oropharyngeal carcinomas have
been shown to have a low EGFR expression.18 Although our
series includes only 1 p16-positive oropharyngeal HNSCC
case, an EGFR H-score of 0 is in accordance with this. The
H-score for GPNMB, however, was 100.
GPNMB seems to have a steadier H-score, with a median
of approximately 100 across all subsites. Furthermore, GPNMB
has a higher NPV than EGFR. Therefore, GPNMB seems to be
more reliable and preferable for NIR fluorescence imaging of
HNSCC in general.
Future studies will have to prove which antibody is more
useful for imaging purposes and whether immunohisto-
chemically detected receptor expression correlates with in
vivo imaging results. Depending on receptor expression pat-
terns in the primary tumor, one of these antibodies may be
more suitable for intraoperative detection of both the pri-
mary tumor and the lymph node metastases simultaneously.
Future studies will therefore have to focus on the primary
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tumor too, as well as on the primary untreated neck, in
which GPNMB has not yet been evaluated.
Conclusions
EGFR and GPNMB showed promising immunohistochem-
ical results as potential molecular imaging targets for the
specific detection of lymph node metastases of HNSCC in
salvage surgery. With a high NPV of 98.2% and 100.0% for
EGFR and GPNMB, respectively, they may facilitate the
surgeon in the identification of tumor-positive lymph nodes.
GPNMB is a promising new molecular imaging target for
HNSCC, which detected all viable tumor cases and could
have prevented 52 of 69 lymph nodes from unnecessary
removal. In our study, it is at least as valuable as EGFR and
should therefore be considered in future molecular imaging
studies. VEGF showed strong staining in all lymph nodes
and therefore seems unsuitable for identification of HNSCC
lymph node metastases after previous (chemo)radiation.
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